Table 1.
Summary of studies on ERG status in HGPIN.
| Reference | % ERG+ HGPIN | Method | Tissue | % with concurrent invasive cancer | Geographic relationship between HGPIN and invasive cancer | Concordance between HGPIN and invasive cancer for ERG status |
|---|---|---|---|---|---|---|
| Cerveira, 2006 (8) | 21% (4/19) | RT-PCR | RP | 100% (19/19) | NS | NS |
| Perner, 2007 (9) | 19% (5/26) | FISH | RP (TMA) | 100% (26/26) | 100% of ERG+ HGPIN in “tight proximity” to cancer | 80% (4/5) for ERG+ HGPIN |
| Furusato, 2008 (10) | 14% (2/14) | RT-PCR | RP | 100% (14/14) | 36% (5/14) adjacent; 64% (9/14) distant | NS |
| Mosquera, 2008 (11) | 16% (23/143) | FISH | RP, Bx | 87% (124/143) | NS | 73% (91/124) |
| Carver et al, 2009 (12) | 10% (4/10) | FISH | RP (TMA) | 100% (10/10) | adjacent | 100% (10/10) |
| Han, 2009 (13) | 15% (5/33) | FISH | RP (TMA) | 100% (33/33) | Adjacent = <3 mm; away = >3 mm | 75% (15/20) for HGPIN adjacent to ERG+ cancer; 0% (0/10) for HGPIN away from ERG+ cancer |
| Han, 2010 (14) | 0% (0/16) | FISH | RP | 100% (16/16) | >3 mm | NS |
| van Leenders, 2011 (15) | 52% (11/21) | IHC | Bx | 90% (19/21) | Same slide | 95% (18/19) |
| Yaskiv, 2011 (16) | 29% (5/17) | IHC | Bx | 100% (17/17) | 71% (12/17) immediately adjacent to invasive carcinoma | 100% (5/5) for ERG+ HGPIN |
| Gao, 2012 (17) | 36% (59/162) | FISH | Bx | 37% (61/162) with subsequent invasive carcinoma | NS | NS |
| He, 2012 (18) | 5% (5/94) | IHC | Bx | 38% (36/94) with subsequent invasive carcinoma | NS | NS |
| Tomlins, 2012 (19) | 18% (12/68) | IHC | Bx | 22% (15/68) | Separate core | 40% (6/15) |
| Liu, 2013 (20) | 22% (4/18) | IHC | Bx | 72% (13/18) | Separate core | NS |
| Lotan, 2013 (21) | 13% (5/39) | IHC | RP | 100% (39/39) | 23 PIN <3mm from PCa and 16 PIN >3mm from Pca | 57% (17/30) |
| Teng, 2013 (22) | 7% (2/29) | IHC | RP (TMA) | 100% (29/29) | NS | 100% (2/2) for ERG+ HGPIN |
| Teng, 2013 (23) | 6% (4/69) | IHC | RP (TMA) | 100% (69/69) | NS | NS |
| Verdu, 2013 (24) | 0% (0/10) | IHC | RP (TMA) | 100% (10/10) | “Distant” | 80% (8/10) |
| Park, 2014 (25) | 11% (51/461) | IHC | Bx | 37% (170/461) with subsequent invasive carcinoma | NS | NS |
| Taris, 2014 (26) | 18% (10/57) | IHC | RP (TMA) | 100% (57/57) | NS | NS |
| Lee, 2015 (27) | 27% (12/45) | IHC | Bx | 20% (9/45) | Same core | 100% (9/9) |
| Morais, 2015 (28) | 0% (0/19) | IHC | Bx | 0% (0/19) | NA | NA |